Assembly Biosciences Inc (ASMB)

Currency in USD
34.380
+0.850(+2.54%)
Closed·
35.000+0.620(+1.80%)
·
ASMB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
33.86035.620
52 wk Range
20.23039.705
Key Statistics
Prev. Close
33.53
Open
33.86
Day's Range
33.86-35.62
52 wk Range
20.23-39.705
Volume
341.54K
Average Volume (3m)
236.56K
1-Year Change
27.6643%
Book Value / Share
15.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ASMB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
50.000
Upside
+45.43%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Assembly Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 50.000
(+45.43% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy50.00+45.43%-MaintainAug 18, 2026
Mizuho
Buy45.00+30.89%40.00MaintainJun 15, 2026
Guggenheim
Buy43.00+25.07%39.00MaintainApr 06, 2026
Jefferies
Buy62.00+80.34%35.00MaintainDec 10, 2025
Mizuho
Buy40.00+16.35%29.00MaintainNov 19, 2025

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.20 / -0.73
Revenue / Forecast
13.37M / 8.6M
EPS Revisions
Last 90 days

ASMB Income Statement

Compare ASMB to Peers and Sector

Metrics to compare
ASMB
Peers
Sector
Relationship
P/E Ratio
−16,666.6x−1.6x−0.4x
PEG Ratio
-−0.040.00
Price/Book
2.3x2.4x2.6x
Price / LTM Sales
9.4x6.6x3.1x
Upside (Analyst Target)
38.2%108.7%48.9%
Fair Value Upside
Unlock15.5%6.2%Unlock

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.49M7.32%51.26M
Other Institutional Investors
21.75M92.68%747.87M
Public Companies & Retail Investors
0.000.00%0.00
Total
23.24M100.00%799.13M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Gilead Sciences, Inc.24.44%4,977,089171,112
Farallon Capital Management, L.L.C.7.88%1,604,59055,166

People Also Watch

66.61
MXL
+2.04%
152.57
NBIX
-0.24%
835.74
CASY
+0.89%
15.75
ANGO
-0.44%

FAQ

What Is the Assembly Biosciences (ASMB) Stock Price Today?

The Assembly Biosciences stock price today is 34.380 USD.

What Stock Exchange Does Assembly Biosciences Trade On?

Assembly Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Assembly Biosciences?

The stock symbol for Assembly Biosciences is "ASMB."

What Is the Assembly Biosciences (ASMB) Afterhours Price Today? (Afterhours variable test: 35.000) Current Date: Aug 23, 2026

After hours price: 35.000. After hours price change (units): 0.620. Price change percentage: 1.800%

What Is the Assembly Biosciences Market Cap?

As of today, Assembly Biosciences market cap is 700.000M USD.

What Is Assembly Biosciences's Earnings Per Share (TTM)?

The Assembly Biosciences EPS (TTM) is -0.003.

When Is the Next Assembly Biosciences Earnings Date?

Assembly Biosciences will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is ASMB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Assembly Biosciences Stock Split?

Assembly Biosciences has split 2 times.

How Many Employees Does Assembly Biosciences Have?

Assembly Biosciences has 73 employees.

What is the current trading status of Assembly Biosciences (ASMB)?

As of Aug 23, 2026, Assembly Biosciences (ASMB) is trading at a price of 34.380 USD, with a previous close of 33.530 USD. The stock has fluctuated within a day range of 33.860 USD to 35.620 USD, while its 52-week range spans from 20.230 USD to 39.705 USD.

What Is Assembly Biosciences (ASMB) Price Target According to Analysts?

The average 12-month price target for Assembly Biosciences is 50.000 USD, with a high estimate of 62 USD and a low estimate of 43 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +45.43% Upside potential.

What Is the ASMB Premarket Price?

ASMB's last pre-market stock price is 34.177 USD. The pre-market share volume is 100.000, and the stock has decreased by 0.647, or 1.930%.

What Is the ASMB After Hours Price?

ASMB's last after hours stock price is 35.000 USD, the stock has decreased by 0.620, or 1.800%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.